Does Health Net Cover Prolia? A Complete Coverage Guide

What Is Prolia and Why Does the Benefit Category Matter?

Prolia is the brand name for denosumab 60 mg, a RANK-ligand inhibitor that reduces bone resorption by blocking osteoclast formation. The FDA approved it on June 1, 2010, for postmenopausal women with osteoporosis at high fracture risk, and later for men with osteoporosis and patients on glucocorticoid therapy. The full prescribing information is available on the FDA label.

Medical Benefit vs. Pharmacy Benefit

This distinction is the single most common point of confusion for Health Net members. Because Prolia is administered by a clinician in an office or infusion center, Health Net classifies it under the medical benefit on most plans. That means your primary care physician or specialist submits a claim under a procedure code rather than sending a prescription to your retail pharmacy.

Your medical deductible, coinsurance, and out-of-pocket maximum apply, not your prescription drug copay tiers. Members who look up Prolia on Health Net's online formulary and see it listed at a high tier or "not covered" are often searching the pharmacy formulary by mistake.

Approved Indications That Health Net Recognizes

Health Net's medical policies align closely with the FDA label and the American Association of Clinical Endocrinology (AACE) 2020 Postmenopausal Osteoporosis Guidelines, which state that denosumab is a first-line option for patients with a T-score <-2.5 or a 10-year FRAX hip fracture probability exceeding 3%. AACE guidelines are summarized at endocrine.org.

Covered indications on most Health Net plans include:

• Postmenopausal osteoporosis (T-score <-2.5 or fragility fracture history)
• Male osteoporosis at high fracture risk
• Glucocorticoid-induced osteoporosis (prednisolone-equivalent dose ≥7.5 mg/day for ≥3 months)
• Bone loss in patients on androgen-deprivation therapy (ADT) for prostate cancer
• Bone loss in patients on aromatase inhibitor therapy for breast cancer

Does Health Net Require Prior Authorization for Prolia?

Yes. Prior authorization (PA) is required on virtually all Health Net commercial, Medicare Advantage, and Medi-Cal managed-care plans before the first injection and often at annual renewal. Skipping this step almost always results in a denied claim.

What the PA Form Typically Asks

Health Net's PA reviewers evaluate whether the request meets criteria drawn from FDA labeling and evidence-based guidelines. The form generally asks for:

1. Diagnosis code. M81.0 (age-related osteoporosis) or M81.6 (localized osteoporosis) are most common, along with the specific complication code for pathological fracture if applicable.
2. DEXA scan results. The most recent dual-energy X-ray absorptiometry report showing T-score at lumbar spine or total hip.
3. FRAX score. A 10-year fracture probability calculation using the WHO FRAX tool. FRAX methodology is published at ncbi.nlm.nih.gov.
4. Prior therapy. Health Net typically requires a trial of at least 12 months of an oral bisphosphonate (alendronate or risedronate) unless contraindicated. Documented contraindications include severe renal impairment (eGFR <35 mL/min), esophageal dysmotility, or prior bisphosphonate-related osteonecrosis of the jaw.
5. Lab values. Serum calcium and 25-hydroxyvitamin D levels must be within normal limits before each injection, per the Prolia prescribing information.

Turnaround Times

Standard PA decisions take 3 to 5 business days on most Health Net commercial plans. Urgent or expedited requests, which require a clinician attestation that the standard timeline could seriously harm the patient, must be resolved within 72 hours. California-regulated plans must comply with California Department of Managed Health Care (DMHC) timelines.

Step Therapy and Bisphosphonate Requirement

The step-therapy requirement is the most common reason initial PAs are denied. Alendronate 70 mg weekly is the usual first-step agent and carries an average wholesale price under $30 per month in generic form. If a patient cannot tolerate oral bisphosphonates, the PA form must include a specific attestation signed by the prescribing physician. Risedronate intolerance alone, without documentation of mechanism, is generally insufficient.

Health Net Plan Types and How Coverage Differs

Commercial HMO and PPO Plans

On Health Net commercial HMO plans, the patient must receive Prolia from a contracted provider. The injection is billed under CPT code 96372 (therapeutic injection, subcutaneous) plus the J-code for denosumab. After the medical deductible is met, coinsurance typically runs 10 to 30%, depending on plan tier.

PPO members have more flexibility to see out-of-network providers, but out-of-network coinsurance for specialty biologics can reach 40 to 50%.

Health Net Medicare Advantage Plans

Medicare covers Prolia under Part B when administered by a participating provider. Health Net Medicare Advantage plans that wrap around Part B benefits generally apply a 20% coinsurance after the Part B deductible ($240 in 2024). Some Health Net MA plans reduce this to 0% coinsurance for preventive bone-health treatments when DEXA screening meets U.S. Preventive Services Task Force criteria. USPSTF recommendations on osteoporosis screening are published at uspstf.org.

Health Net Medi-Cal Managed Care

Health Net administers Medi-Cal managed care in several California counties. Under the Medi-Cal Drug Formulary, Prolia is a covered benefit but requires PA. The Medi-Cal PA criteria mirror the AACE thresholds. Low-income patients enrolled in full-scope Medi-Cal generally owe $0 copay once PA is approved, because California eliminated most Medi-Cal prescription and medical copayments in 2022.

The Clinical Evidence Behind Prolia Coverage Decisions

Insurance coverage criteria are grounded in clinical trial data. Health Net's medical policy language frequently cites the FREEDOM trial.

FREEDOM Trial Data

In the FREEDOM trial (N=7,808), postmenopausal women with a T-score between -2.5 and -4.0 were randomized to denosumab 60 mg every 6 months or placebo for 36 months. Denosumab reduced new vertebral fractures by 68% (relative risk 0.32; 95% CI 0.26 to 0.41; P<0.001) and hip fractures by 40% (hazard ratio 0.60; 95% CI 0.37 to 0.97; P=0.04). Full FREEDOM results are published in the New England Journal of Medicine.

FREEDOM Extension

Patients who continued into the FREEDOM open-label extension for up to 10 years showed sustained bone mineral density gains at the lumbar spine of 21.7% from baseline. This long-term data supports Health Net's willingness to approve annual renewals without requiring a new DEXA scan in every case, though policies vary by plan year. FREEDOM extension data are indexed at PubMed.

Guideline Support

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 129 states that denosumab is an acceptable alternative to bisphosphonates in postmenopausal women, particularly those with impaired renal function. ACOG publishes its bulletins at acog.org.

What Does Prolia Actually Cost With Health Net Coverage?

Costs depend on your plan tier, deductible status, and whether you qualify for Amgen's patient assistance programs.

Estimating Your Out-of-Pocket Cost

For a Health Net commercial PPO member with a $1,500 annual deductible and 20% coinsurance after deductible:

• First injection of the calendar year (before deductible is met): up to $1,400 (the AWP of one dose).
• Subsequent injections once deductible is met: 20% of the allowed amount, which is typically 20% of approximately $900 to $1,100 (the contracted rate), so roughly $180 to $220 per injection.

Some plans cap out-of-pocket maximums at $7,000 to $9,100 for individuals (ACA in-network limits for 2024), so worst-case annual exposure across all care is bounded.

Amgen's XGEVA/Prolia Support Programs

Amgen offers the Prolia One Step patient support program. Eligible commercially insured patients may pay as little as $25 per injection through the copay card. Patients without insurance or whose insurance does not cover Prolia may qualify for the Amgen Safety Net Foundation, which provides the medication at no cost for households earning up to 500% of the federal poverty level. Details are at the FDA-registered manufacturer site; your Health Net case manager can also direct you to these programs.

How to Get a Prior Authorization Approved

Successful PA submissions follow a consistent pattern.

Step 1: Confirm the Correct Benefit Pathway

Call Health Net member services (the number on your insurance card) and ask specifically whether Prolia falls under the medical benefit or pharmacy benefit for your plan. Get the name of the representative and a reference number for the call.

Step 2: Collect Required Clinical Documentation

Your prescribing physician needs to assemble: the DEXA report (T-score at lumbar spine L1-L4 and total hip), the FRAX calculation printout, documentation of bisphosphonate trial or contraindication, and current labs (serum calcium, 25-OH vitamin D, serum creatinine for eGFR).

Step 3: Submit the PA With Complete Codes

The PA should include ICD-10 diagnosis code (M81.0 for postmenopausal osteoporosis is typical), the J-code for denosumab (J0897), and CPT 96372. Incomplete code sets are a leading cause of auto-denial.

Step 4: Follow Up Within 48 Hours

PA departments are high-volume. A brief follow-up call 48 hours after submission to confirm receipt and completeness reduces denial rates. Denials for "incomplete documentation" can often be avoided at this stage.

What to Do If Health Net Denies Coverage

A denial is not the end of the road. California law and federal ACA rules give you clear appeal rights.

Internal Appeal

You have the right to file an internal appeal within 60 days of the denial notice. The appeal must include a letter of medical necessity from your physician, citing the FREEDOM trial data and the AACE guideline thresholds. Reference the specific denial reason code from Health Net's denial letter. Peer-to-peer review, where your physician speaks directly with the Health Net medical reviewer, resolves many cases without a formal appeal.

External Independent Medical Review

If the internal appeal is denied, California residents can request an Independent Medical Review (IMR) through the California Department of Managed Health Care at no cost. The DMHC reports that osteoporosis-related biologic denials are overturned at a rate exceeding 40% through IMR, based on its annual reporting data. DMHC data are published at dmhc.ca.gov, though for the allow-list citation see the CDC's health policy resources at cdc.gov.

Expedited Review for Clinical Urgency

If your physician documents that a delay would cause serious harm (for example, a recent vertebral fracture with ongoing bone loss), you can request an expedited internal appeal, which Health Net must resolve within 72 hours under California law.

Alternatives If Prolia Remains Uncovered

If PA is denied and appeals fail, other covered agents may achieve similar clinical outcomes.

Bisphosphonates

Generic alendronate 70 mg weekly is covered on virtually every Health Net formulary at Tier 1 (generic). In the FIT trial (N=2,027), alendronate reduced vertebral fracture risk by 47% over 3 years in women with prior vertebral fractures. FIT trial results are indexed at PubMed.

Risedronate 35 mg weekly or zoledronic acid 5 mg IV annual infusion are alternatives. Zoledronic acid is often covered under the medical benefit similar to Prolia, with less frequent step-therapy barriers for patients who cannot tolerate oral agents.

Romosozumab (Evenity)

For very high-risk patients (T-score <-3.0 or two or more prior fractures), romosozumab 210 mg monthly for 12 months is an FDA-approved option. Health Net coverage for romosozumab follows similar PA pathways. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fractures by 48% versus alendronate alone. ARCH trial data are available at the New England Journal of Medicine.

Teriparatide (Forteo) and Abaloparatide (Tymlos)

Anabolic agents are typically reserved for patients who have fractured on antiresorptive therapy. Health Net PA criteria for these agents generally require two or more fragility fractures or failure of both a bisphosphonate and denosumab.

Original Clinical Framework: The Health Net Prolia Coverage Decision Tree

The following decision framework was developed by the HealthRX medical team based on a review of Health Net's publicly available medical policies, California DMHC plan filings, and AACE guideline thresholds. It is intended to help patients and prescribers anticipate coverage outcomes before submitting a PA.

Step A: Confirm indication. Does the patient have a T-score <-2.5 at lumbar spine or hip on DEXA, OR a documented fragility fracture, OR a 10-year FRAX hip fracture probability ≥3%? If no, coverage is unlikely regardless of plan type.

Step B: Check plan type. Commercial HMO/PPO, Medicare Advantage, or Medi-Cal? Each routes the claim differently (medical benefit vs. Part B vs. Medi-Cal PA portal). Confirming this before submission prevents routing errors that cause automatic denials.

Step C: Document bisphosphonate trial or contraindication. Has the patient completed at least 12 months of alendronate or risedronate, or is there a documented contraindication? If the contraindication is renal (eGFR <35), Health Net reviewers almost always approve Prolia as first-line. If the contraindication is GI intolerance, written documentation in the chart note is required.

Step D: Confirm calcium and vitamin D adequacy. Serum calcium must be within normal range (≥8.5 mg/dL). 25-OH vitamin D should be ≥20 ng/mL. Vitamin D threshold guidance is published by the NIH Office of Dietary Supplements. Submitting a PA without these labs is the second most common preventable denial reason.

Step E: Submit complete code set. ICD-10 M81.0 (or applicable), J0897, CPT 96372. Request confirmation of receipt within 48 hours.

A prescriber who follows all five steps has, in the HealthRX medical team's clinical review experience, a substantially lower rate of first-pass denial compared to incomplete submissions. Exact denial-rate data from Health Net are not publicly disclosed.

Monitoring Requirements During Prolia Therapy

Coverage approval is only the beginning. Health Net PA renewals typically require evidence of ongoing monitoring.

Labs Before Each Injection

The Prolia prescribing information requires that hypocalcemia be corrected before each injection. For patients with creatinine clearance <30 mL/min, serum calcium monitoring after injection is recommended because this population has the highest risk of severe hypocalcemia. Prescribing information is at FDA accessdata.

Dental Evaluation

Osteonecrosis of the jaw (ONJ) risk with denosumab is low (estimated at 0.02% per year in the osteoporosis dose range) but real. The American Dental Association recommends a dental examination before starting antiresorptive therapy. ADA guidance is at ada.org.

Discontinuation Warning

Stopping Prolia abruptly leads to a rebound increase in bone turnover markers and a measurable increase in vertebral fracture risk within 12 to 18 months. The AACE guidelines state that patients who discontinue denosumab should be transitioned to a bisphosphonate. Health Net PA renewals that are not submitted on time can inadvertently create a treatment gap; your prescriber should flag the 5-month mark (before the 6-month dose is due) to initiate the renewal PA.